Description

ARTVIGIL 150 MG

Indications

ARTVIGIL 150 MG is primarily indicated for the treatment of narcolepsy, a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. It is also used to manage shift work sleep disorder, which affects individuals who work non-traditional hours and experience difficulties in maintaining a regular sleep pattern. Additionally, ARTVIGIL may be prescribed for attention deficit hyperactivity disorder (ADHD) in certain cases, particularly when traditional stimulant medications are not suitable.

Mechanism of Action

The active ingredient in ARTVIGIL is modafinil, a wakefulness-promoting agent. The exact mechanism of action is not fully understood; however, it is believed to involve the modulation of neurotransmitters in the brain, particularly dopamine. Modafinil enhances dopaminergic signaling by inhibiting the reuptake of dopamine, which leads to increased levels of this neurotransmitter in the synaptic cleft. This action promotes alertness and reduces excessive sleepiness. Additionally, modafinil may affect other neurotransmitter systems, including norepinephrine and serotonin, contributing to its wakefulness-promoting effects.

Pharmacological Properties

ARTVIGIL exhibits several pharmacological properties that make it effective in promoting wakefulness. It is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 2 to 4 hours. The drug has a half-life of approximately 12 to 15 hours, allowing for once-daily dosing in most cases. ARTVIGIL is primarily metabolized in the liver, with the majority of its metabolites being excreted in the urine. The pharmacokinetics of modafinil can be influenced by factors such as age, liver function, and the use of concomitant medications.

Contraindications

ARTVIGIL is contraindicated in individuals with a known hypersensitivity to modafinil or any of the excipients present in the formulation. It should not be used in patients with a history of serious skin reactions, including Stevens-Johnson syndrome or toxic epidermal necrolysis, associated with modafinil use. Additionally, ARTVIGIL is not recommended for use in patients with severe hepatic impairment, as this may lead to increased plasma levels of the drug and heightened risk of adverse effects.

Side Effects

Common side effects associated with ARTVIGIL include headache, nausea, dizziness, and insomnia. These effects are generally mild to moderate in severity and may diminish with continued use. Serious side effects, although rare, can occur and may include severe allergic reactions, skin rashes, and psychiatric symptoms such as anxiety, depression, or hallucinations. Patients should be monitored for any unusual changes in mood or behavior, particularly during the initial treatment period.

Dosage and Administration

The recommended dosage of ARTVIGIL for adults is typically 150 mg once daily, taken in the morning. For patients with shift work sleep disorder, the dose may be administered approximately one hour before the start of the work shift. It is important to follow the prescribing physician’s instructions regarding dosage adjustments, especially in special populations such as the elderly or those with hepatic impairment. ARTVIGIL can be taken with or without food, and patients should be advised to swallow the tablet whole without chewing or crushing.

Interactions

ARTVIGIL may interact with various medications, potentially altering their effectiveness or increasing the risk of side effects. Notable interactions include those with oral contraceptives, as modafinil may reduce their efficacy, leading to unintended pregnancy. Additionally, ARTVIGIL can affect the metabolism of certain medications, such as warfarin and some antiepileptic drugs, necessitating careful monitoring of therapeutic levels. Patients should inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Before initiating treatment with ARTVIGIL, a thorough medical history should be obtained, particularly regarding any history of cardiovascular disease, liver impairment, or psychiatric disorders. Patients should be advised to use caution when driving or operating machinery until they know how ARTVIGIL affects them, as the drug may cause dizziness or affect cognitive function. Regular follow-up appointments are recommended to assess the effectiveness of treatment and monitor for any adverse effects or complications.

Clinical Studies

Numerous clinical studies have evaluated the efficacy and safety of ARTVIGIL in treating narcolepsy and shift work sleep disorder. In randomized controlled trials, modafinil has demonstrated significant improvements in wakefulness and a reduction in excessive daytime sleepiness compared to placebo. Patients reported enhanced quality of life and improved functioning in daily activities. Long-term studies have also indicated that ARTVIGIL is generally well-tolerated, with a favorable safety profile when used as directed. However, ongoing research continues to explore its effects in different populations and its potential use in other conditions, such as ADHD.

Conclusion

ARTVIGIL 150 MG is an effective treatment option for individuals suffering from narcolepsy and shift work sleep disorder. Its unique mechanism of action and pharmacological properties contribute to its ability to promote wakefulness and improve overall quality of life. While generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. Regular monitoring and communication with healthcare providers are crucial to ensure the safe and effective use of ARTVIGIL.